Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Verseon Corp    VSN

VERSEON CORP (VSN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
122.5(c) 127.5(c) 132.5(c) 134.5(c) 142.5(c) Last
485 912 11 000 16 000 3 000 12 000 Volume
+9.87% +4.08% +3.92% +1.51% +5.95% Change
More quotes
Financials (GBP)
More Financials
Company
Verseon Corp. engages in the development and design of pharmaceutical products.It focuses on drug discovery technology to seed a growing portfolio of programs targeting diverse disease areas, currently consisting of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.The... 
More about the company
Latest news on VERSEON CORP
06/21VERSEON : to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagula..
AQ
06/21VERSEON : Presents New Data on its Precision Oral Anticoagulants at BIO Internat..
AQ
06/14VERSEON : to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagula..
BU
06/11VERSEON : Presents New Data on its Precision Oral Anticoagulants at BIO Internat..
BU
05/10VERSEON : Presents New Efficacy Results on Oral Diabetic Macular Edema Drug Cand..
AQ
05/03VERSEON : Patent Issued for Halogenopyrazoles as Inhibitors of Thrombin (USPTO 9..
AQ
05/02VERSEON : Presents New Efficacy Results on Oral Diabetic Macular Edema Drug Cand..
BU
04/26VERSEON : Presents Anticancer Drug Candidates Targeting Multidrug Resistant Canc..
AQ
04/18VERSEON : Presents Anticancer Drug Candidates Targeting Multidrug Resistant Canc..
BU
01/11VERSEON : s Plasma Kallikrein Treatment "Well-Suited" For Oral Dosage
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/10elsewhere in??:? ???Sygnis $LIO1 +4% 4SC $VSC +3.5% ??Cosmo $COPN +4.5% ??Sum.. 
06/27Lifesize Appoints SaaS Marketing Leader Anirban Datta as Chief Marketing Offi.. 
06/25Verseon maintains losses as it seeks to monetise platform  
06/14Verseon to Initiate Ph I Study of New Class Anticoagulant with Reduced Bleedi..
1
06/14Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagul.. 
More tweets
Qtime:41
Chart VERSEON CORP
Duration : Period :
Verseon Corp Technical Analysis Chart | VSN | USU9221J1098 | 4-Traders
Technical analysis trends VERSEON CORP
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Managers
NameTitle
Adityo Prakash Chief Executive Officer & Executive Director
Thomas Arnold Hecht Non-Executive Chairman
Eniko Fodor Chief Operating & Financial Officer
David Kita Vice President-Research & Development
Grover T. Wickersham Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
VERSEON CORP17.28%266
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147